ARDT Ardent Health-18.9%Stock move

Ardent Health Stock Falls 19% on Filing for Offering by Selling Stockholders

Selling stockholders filed to offer 8 million shares in a prospectus supplement made the evening before the session.

A team of surgeons wearing surgical suits while performing an operation in a fully quipped operating room
Photo: Juice Verve/Shutterstock.com

Key points

  • Ardent Health (ARDT) fell 18.9% on Nov. 18 to $14.40 as an 8 million share secondary offering was filed the evening before
  • Selling stockholders offered 8,000,000 shares; underwriters hold an option for 1,200,000 more
  • Ardent plans to repurchase up to 1,500,000 of the offered shares at the offering price
  • Q3 2026 net income was $44.5 million on revenue of $1.62 billion

Ardent Health (NYSE: ARDT) fell 18.9% on Wednesday to close at $14.40, down from $17.75 at the previous close, on heavy trading of about 13.4 times normal volume. The S&P 500 ETF (SPY) moved -0.31% that session.

The move followed a prospectus supplement filed in a 424B5 at 5:24 p.m. ET on Nov. 17, the evening before the session. The filing registers an offering of 8,000,000 shares of common stock by selling stockholders, with underwriters holding an option to buy up to 1,200,000 more. J.P. Morgan, Barclays, BofA Securities, Citigroup and others are named as underwriters.

Company repurchase tied to the offering

The filing also says Ardent intends to repurchase up to 1,500,000 of the offered shares from the underwriters at the same price paid to the selling stockholders, using cash on hand. The company says the offering is not conditioned on that repurchase, and that the repurchase is outside its existing buyback plan.

Controlling holder remains in place

EGI-AM Investments, an affiliate of Equity Group Investments, is the company's controlling stockholder. The filing says EGI-AM would hold about 50.3% of the voting power after the offering and the repurchase, or about 49.5% if the underwriters exercise their option in full.

Financial backdrop

In the latest reported quarter, ended Sept. 30, 2026, Ardent reported revenue of $1.62 billion, up 3% from a year earlier, and net income of $44.5 million, compared with a loss of $23.5 million a year earlier. Cash and equivalents were $766.2 million as of that date.

Sources

Written with AI from SEC filings and market data, and checked against those sources before publishing. Our editorial standards.

Other stock movers this week

ARDT page →

Filings, figures and price history are on the Ardent Health page.